APO Research
Talk to an analyst

APO RESEARCH · REPORT

NGS for Multi-cancer Early Screening

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NGS for Multi-cancer Early Screening Market Outlook and Growth Opportunities 2026

15 April 2026Not stated

Choose your research edition.

Industry ResearchNGS for Multi-cancer Early Screening Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal NGS for Multi-cancer Early Screening Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal NGS for Multi-cancer Early Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NGS for Multi-cancer Early Screening Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal NGS for Multi-cancer Early Screening Market Analysis and Forecast 2026-2032255 pages · $4,950 USD

Market perspective

The global NGS for Multi-cancer Early Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NGS for Multi-cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NGS for Multi-cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NGS for Multi-cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NGS for Multi-cancer Early Screening market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NGS for Multi-cancer Early Screening market include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global NGS for Multi-cancer Early Screening market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NGS for Multi-cancer Early Screening and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NGS for Multi-cancer Early Screening revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global NGS for Multi-cancer Early Screening market.

NGS for Multi-cancer Early Screening Segment by Company

Guardant Health

Exact Sciences

Freenome

Epiginomics AG

Bio-techne

ThriveEarlier Detection

GRAIL, Inc.

CellMax life

Berry Genomics

Singlera Genomics

Geneseeq

Burning Rock Biotech Limited

New Horizon Health Limited

NGS for Multi-cancer Early Screening Segment by Type

ctDNA Gene Mutation Detection

cfDNA Methylation Sequencing

NGS for Multi-cancer Early Screening Segment by Application

Medical Institutions

Physical Examination Centers

NGS for Multi-cancer Early Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global NGS for Multi-cancer Early Screening status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the NGS for Multi-cancer Early Screening key companies, revenue, market share, and recent developments.

3. To split the NGS for Multi-cancer Early Screening breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions NGS for Multi-cancer Early Screening market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NGS for Multi-cancer Early Screening significant trends, drivers, influence factors in global and regions.

6. To analyze NGS for Multi-cancer Early Screening competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGS for Multi-cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NGS for Multi-cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGS for Multi-cancer Early Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NGS for Multi-cancer Early Screening industry.

Chapter 3: Detailed analysis of NGS for Multi-cancer Early Screening company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of NGS for Multi-cancer Early Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of NGS for Multi-cancer Early Screening in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NGS for Multi-cancer Early Screening Industry Trends Table 2. NGS for Multi-cancer Early Screening Industry Drivers Table 3. NGS for Multi-cancer Early Screening Industry Opportunities and Challenges Table 4. NGS for Multi-cancer Early Screening Industry Restraints Table 5. Global NGS for Multi-cancer Early Screening Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NGS for Multi-cancer Early Screening Revenue Share by Company (2021-2026) Table 7. Global NGS for Multi-cancer Early Screening Company Ranking, (2024-2026) & (US$ Million) Table 8. Global NGS for Multi-cancer Early Screening Key Company Manufacturing Base & Headquarters Table 9. Global NGS for Multi-cancer Early Screening Company, Product Type & Application Table 10. Global NGS for Multi-cancer Early Screening Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global NGS for Multi-cancer Early Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of ctDNA Gene Mutation Detection Table 15. Significant Companies of cfDNA Methylation Sequencing Table 16. Global NGS for Multi-cancer Early Screening Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global NGS for Multi-cancer Early Screening Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global NGS for Multi-cancer Early Screening Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global NGS for Multi-cancer Early Screening Sales Value Share by Type (2021-2026) Table 20. Global NGS for Multi-cancer Early Screening Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Medical Institutions Table 22. Significant Companies of Physical Examination Centers Table 23. Global NGS for Multi-cancer Early Screening Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global NGS for Multi-cancer Early Screening Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global NGS for Multi-cancer Early Screening Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global NGS for Multi-cancer Early Screening Sales Value Share by Application (2021-2026) Table 27. Global NGS for Multi-cancer Early Screening Sales Value Share by Application (2027-2032) Table 28. Global NGS for Multi-cancer Early Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global NGS for Multi-cancer Early Screening Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global NGS for Multi-cancer Early Screening Sales Value Share by Region (2021-2026) Table 31. Global NGS for Multi-cancer Early Screening Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global NGS for Multi-cancer Early Screening Sales Value Share by Region (2027-2032) Table 33. Global NGS for Multi-cancer Early Screening Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global NGS for Multi-cancer Early Screening Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global NGS for Multi-cancer Early Screening Sales Value Market Share by Country (2021-2026) Table 36. Global NGS for Multi-cancer Early Screening Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global NGS for Multi-cancer Early Screening Sales Value Market Share by Country (2027-2032) Table 38. Guardant Health Company Information Table 39. Guardant Health Business Overview Table 40. Guardant Health NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Guardant Health NGS for Multi-cancer Early Screening Product Portfolio Table 42. Guardant Health Recent Development Table 43. Exact Sciences Company Information Table 44. Exact Sciences Business Overview Table 45. Exact Sciences NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Exact Sciences NGS for Multi-cancer Early Screening Product Portfolio Table 47. Exact Sciences Recent Development Table 48. Freenome Company Information Table 49. Freenome Business Overview Table 50. Freenome NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Freenome NGS for Multi-cancer Early Screening Product Portfolio Table 52. Freenome Recent Development Table 53. Epiginomics AG Company Information Table 54. Epiginomics AG Business Overview Table 55. Epiginomics AG NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Epiginomics AG NGS for Multi-cancer Early Screening Product Portfolio Table 57. Epiginomics AG Recent Development Table 58. Bio-techne Company Information Table 59. Bio-techne Business Overview Table 60. Bio-techne NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Bio-techne NGS for Multi-cancer Early Screening Product Portfolio Table 62. Bio-techne Recent Development Table 63. ThriveEarlier Detection Company Information Table 64. ThriveEarlier Detection Business Overview Table 65. ThriveEarlier Detection NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. ThriveEarlier Detection NGS for Multi-cancer Early Screening Product Portfolio Table 67. ThriveEarlier Detection Recent Development Table 68. GRAIL, Inc. Company Information Table 69. GRAIL, Inc. Business Overview Table 70. GRAIL, Inc. NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. GRAIL, Inc. NGS for Multi-cancer Early Screening Product Portfolio Table 72. GRAIL, Inc. Recent Development Table 73. CellMax life Company Information Table 74. CellMax life Business Overview Table 75. CellMax life NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. CellMax life NGS for Multi-cancer Early Screening Product Portfolio Table 77. CellMax life Recent Development Table 78. Berry Genomics Company Information Table 79. Berry Genomics Business Overview Table 80. Berry Genomics NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Berry Genomics NGS for Multi-cancer Early Screening Product Portfolio Table 82. Berry Genomics Recent Development Table 83. Singlera Genomics Company Information Table 84. Singlera Genomics Business Overview Table 85. Singlera Genomics NGS for Multi-cancer Early Screening Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Singlera Genomics NGS for Multi-cancer Early Screening Product Portfolio Table 87. Singlera Genomics Recent Development Table 88. Geneseeq Company Information Table 89. Geneseeq Business Overview Table 90. Geneseeq NGS for Multi-cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Geneseeq NGS for Multi-cancer Early Screening Product Portfolio Table 92. Geneseeq Recent Development Table 93. Burning Rock Biotech Limited Company Information Table 94. Burning Rock Biotech Limited Business Overview Table 95. Burning Rock Biotech Limited NGS for Multi-cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Burning Rock Biotech Limited NGS for Multi-cancer Early Screening Product Portfolio Table 97. Burning Rock Biotech Limited Recent Development Table 98. New Horizon Health Limited Company Information Table 99. New Horizon Health Limited Business Overview Table 100. New Horizon Health Limited NGS for Multi-cancer Early Screening Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. New Horizon Health Limited NGS for Multi-cancer Early Screening Product Portfolio Table 102. New Horizon Health Limited Recent Development Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. NGS for Multi-cancer Early Screening Product Image Figure 2. Global NGS for Multi-cancer Early Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NGS for Multi-cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 4. Global NGS for Multi-cancer Early Screening Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. ctDNA Gene Mutation Detection Image Figure 8. cfDNA Methylation Sequencing Image Figure 9. Global NGS for Multi-cancer Early Screening Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global NGS for Multi-cancer Early Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global NGS for Multi-cancer Early Screening Sales Value Share by Type (2021-2032) Figure 12. Medical Institutions Image Figure 13. Physical Examination Centers Image Figure 14. Global NGS for Multi-cancer Early Screening Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global NGS for Multi-cancer Early Screening Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global NGS for Multi-cancer Early Screening Sales Value Share by Application (2021-2032) Figure 17. Global NGS for Multi-cancer Early Screening Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global NGS for Multi-cancer Early Screening Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America NGS for Multi-cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 20. North America NGS for Multi-cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe NGS for Multi-cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 22. Europe NGS for Multi-cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific NGS for Multi-cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific NGS for Multi-cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America NGS for Multi-cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 26. South America NGS for Multi-cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa NGS for Multi-cancer Early Screening Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa NGS for Multi-cancer Early Screening Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • ctDNA Gene Mutation Detection
  • cfDNA Methylation Sequencing
Applications
  • Medical Institutions
  • Physical Examination Centers
Companies covered
  • Guardant Health
  • Exact Sciences
  • Freenome
  • Epiginomics AG
  • Bio-techne
  • ThriveEarlier Detection
  • GRAIL, Inc.
  • CellMax life
  • Berry Genomics
  • Singlera Genomics
  • Geneseeq
  • Burning Rock Biotech Limited
  • New Horizon Health Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global NGS for Multi-cancer Early Screening Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global NGS for Multi-cancer Early Screening Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 NGS for Multi-cancer Early Screening Market Dynamics
  1. 2.1 NGS for Multi-cancer Early Screening Industry Trends
  2. 2.2 NGS for Multi-cancer Early Screening Industry Drivers
  3. 2.3 NGS for Multi-cancer Early Screening Industry Opportunities and Challenges
  4. 2.4 NGS for Multi-cancer Early Screening Industry Restraints
3 NGS for Multi-cancer Early Screening Market by Company
  1. 3.1 Global NGS for Multi-cancer Early Screening Company Revenue Ranking in 2025
  2. 3.2 Global NGS for Multi-cancer Early Screening Revenue by Company (2021-2026)
  3. 3.3 Global NGS for Multi-cancer Early Screening Company Ranking (2024-2026)
  4. 3.4 Global NGS for Multi-cancer Early Screening Company Manufacturing Base and Headquarters
  5. 3.5 Global NGS for Multi-cancer Early Screening Company Product Type and Application
  6. 3.6 Global NGS for Multi-cancer Early Screening Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global NGS for Multi-cancer Early Screening Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 NGS for Multi-cancer Early Screening Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 NGS for Multi-cancer Early Screening Market by Type
  1. 4.1 NGS for Multi-cancer Early Screening Type Introduction
  2. 4.1.1 ctDNA Gene Mutation Detection
  3. 4.1.2 cfDNA Methylation Sequencing
  4. 4.2 Global NGS for Multi-cancer Early Screening Sales Value by Type
  5. 4.2.1 Global NGS for Multi-cancer Early Screening Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global NGS for Multi-cancer Early Screening Sales Value by Type (2021-2032)
  7. 4.2.3 Global NGS for Multi-cancer Early Screening Sales Value Share by Type (2021-2032)
5 NGS for Multi-cancer Early Screening Market by Application
  1. 5.1 NGS for Multi-cancer Early Screening Application Introduction
  2. 5.1.1 Medical Institutions
  3. 5.1.2 Physical Examination Centers
  4. 5.2 Global NGS for Multi-cancer Early Screening Sales Value by Application
  5. 5.2.1 Global NGS for Multi-cancer Early Screening Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global NGS for Multi-cancer Early Screening Sales Value by Application (2021-2032)
  7. 5.2.3 Global NGS for Multi-cancer Early Screening Sales Value Share by Application (2021-2032)
6 NGS for Multi-cancer Early Screening Regional Value Analysis
  1. 6.1 Global NGS for Multi-cancer Early Screening Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NGS for Multi-cancer Early Screening Sales Value by Region (2021-2032)
  3. 6.2.1 Global NGS for Multi-cancer Early Screening Sales Value by Region: 2021-2026
  4. 6.2.2 Global NGS for Multi-cancer Early Screening Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America NGS for Multi-cancer Early Screening Sales Value (2021-2032)
  7. 6.3.2 North America NGS for Multi-cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe NGS for Multi-cancer Early Screening Sales Value (2021-2032)
  10. 6.4.2 Europe NGS for Multi-cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific NGS for Multi-cancer Early Screening Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific NGS for Multi-cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America NGS for Multi-cancer Early Screening Sales Value (2021-2032)
  16. 6.6.2 South America NGS for Multi-cancer Early Screening Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa NGS for Multi-cancer Early Screening Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa NGS for Multi-cancer Early Screening Sales Value Share by Country, 2025 VS 2032
7 NGS for Multi-cancer Early Screening Country-level Value Analysis
  1. 7.1 Global NGS for Multi-cancer Early Screening Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NGS for Multi-cancer Early Screening Sales Value by Country (2021-2032)
  3. 7.2.1 Global NGS for Multi-cancer Early Screening Sales Value by Country (2021-2026)
  4. 7.2.2 Global NGS for Multi-cancer Early Screening Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt NGS for Multi-cancer Early Screening Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt NGS for Multi-cancer Early Screening Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt NGS for Multi-cancer Early Screening Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Guardant Health
  2. 8.1.1 Guardant Health Company Information
  3. 8.1.2 Guardant Health Business Overview
  4. 8.1.3 Guardant Health NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Guardant Health NGS for Multi-cancer Early Screening Product Portfolio
  6. 8.1.5 Guardant Health Recent Developments
  7. 8.2 Exact Sciences
  8. 8.2.1 Exact Sciences Company Information
  9. 8.2.2 Exact Sciences Business Overview
  10. 8.2.3 Exact Sciences NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Exact Sciences NGS for Multi-cancer Early Screening Product Portfolio
  12. 8.2.5 Exact Sciences Recent Developments
  13. 8.3 Freenome
  14. 8.3.1 Freenome Company Information
  15. 8.3.2 Freenome Business Overview
  16. 8.3.3 Freenome NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Freenome NGS for Multi-cancer Early Screening Product Portfolio
  18. 8.3.5 Freenome Recent Developments
  19. 8.4 Epiginomics AG
  20. 8.4.1 Epiginomics AG Company Information
  21. 8.4.2 Epiginomics AG Business Overview
  22. 8.4.3 Epiginomics AG NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Epiginomics AG NGS for Multi-cancer Early Screening Product Portfolio
  24. 8.4.5 Epiginomics AG Recent Developments
  25. 8.5 Bio-techne
  26. 8.5.1 Bio-techne Company Information
  27. 8.5.2 Bio-techne Business Overview
  28. 8.5.3 Bio-techne NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bio-techne NGS for Multi-cancer Early Screening Product Portfolio
  30. 8.5.5 Bio-techne Recent Developments
  31. 8.6 ThriveEarlier Detection
  32. 8.6.1 ThriveEarlier Detection Company Information
  33. 8.6.2 ThriveEarlier Detection Business Overview
  34. 8.6.3 ThriveEarlier Detection NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ThriveEarlier Detection NGS for Multi-cancer Early Screening Product Portfolio
  36. 8.6.5 ThriveEarlier Detection Recent Developments
  37. 8.7 GRAIL, Inc.
  38. 8.7.1 GRAIL, Inc. Company Information
  39. 8.7.2 GRAIL, Inc. Business Overview
  40. 8.7.3 GRAIL, Inc. NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GRAIL, Inc. NGS for Multi-cancer Early Screening Product Portfolio
  42. 8.7.5 GRAIL, Inc. Recent Developments
  43. 8.8 CellMax life
  44. 8.8.1 CellMax life Company Information
  45. 8.8.2 CellMax life Business Overview
  46. 8.8.3 CellMax life NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CellMax life NGS for Multi-cancer Early Screening Product Portfolio
  48. 8.8.5 CellMax life Recent Developments
  49. 8.9 Berry Genomics
  50. 8.9.1 Berry Genomics Company Information
  51. 8.9.2 Berry Genomics Business Overview
  52. 8.9.3 Berry Genomics NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Berry Genomics NGS for Multi-cancer Early Screening Product Portfolio
  54. 8.9.5 Berry Genomics Recent Developments
  55. 8.10 Singlera Genomics
  56. 8.10.1 Singlera Genomics Company Information
  57. 8.10.2 Singlera Genomics Business Overview
  58. 8.10.3 Singlera Genomics NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Singlera Genomics NGS for Multi-cancer Early Screening Product Portfolio
  60. 8.10.5 Singlera Genomics Recent Developments
  61. 8.11 Geneseeq
  62. 8.11.1 Geneseeq Company Information
  63. 8.11.2 Geneseeq Business Overview
  64. 8.11.3 Geneseeq NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Geneseeq NGS for Multi-cancer Early Screening Product Portfolio
  66. 8.11.5 Geneseeq Recent Developments
  67. 8.12 Burning Rock Biotech Limited
  68. 8.12.1 Burning Rock Biotech Limited Company Information
  69. 8.12.2 Burning Rock Biotech Limited Business Overview
  70. 8.12.3 Burning Rock Biotech Limited NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Burning Rock Biotech Limited NGS for Multi-cancer Early Screening Product Portfolio
  72. 8.12.5 Burning Rock Biotech Limited Recent Developments
  73. 8.13 New Horizon Health Limited
  74. 8.13.1 New Horizon Health Limited Company Information
  75. 8.13.2 New Horizon Health Limited Business Overview
  76. 8.13.3 New Horizon Health Limited NGS for Multi-cancer Early Screening Revenue and Gross Margin (2021-2026)
  77. 8.13.4 New Horizon Health Limited NGS for Multi-cancer Early Screening Product Portfolio
  78. 8.13.5 New Horizon Health Limited Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst